Traditional molecular diagnostic workflows are often complex, time-consuming, and costly, leading to delayed pathogen detection and reduced laboratory efficiency. This complexity can hinder early intervention and impact patient outcomes, while also creating operational and financial strain for diagnostic facilities.

OSPRI provides advanced multiplex molecular assays and integrated laboratory solutions designed to streamline diagnostic processes. Their proprietary direct-to-PCR technology eliminates extraction steps, significantly reducing testing time and complexity. This approach enables faster, more accurate pathogen identification and supports the development of high-performance molecular laboratories. By optimizing workflows and reducing operational overhead, OSPRI empowers laboratories to improve patient care and enhance financial sustainability.

Direct-to-PCR assays that eliminate nucleic acid extraction steps, reducing workflow time by 50-70%.

Quad-plex multiplexing capability, allowing detection of four targets per well to increase throughput.

Extraction-free assay design that minimizes manual handling and reduces consumable costs.

Pre-plated or pre-mixed reagents for direct-to-amplification readiness, minimizing preparation time and potential for human error.

Customizable assay panels to align with specific clinical needs and improve diagnostic relevance.

Scalable laboratory solutions designed to optimize instrument utilization and reduce overhead.

Integrated workflow design, data analytics, and compliance support for building and operating molecular labs.

Primary customers include clinical laboratories, hospital systems, physician office laboratories, and diagnostic startups seeking to enhance their molecular testing capabilities, improve turnaround times, and optimize operational efficiency.